CAR T Cell Therapy Treatments

The FDA has approved 6 CAR T cell therapy treatments. These treatments are typically for patients where the cancer is refractory or relapsed after having 1 or more prior treatments. Refractory means the cancer did not respond to the previous treatment. Relapsed means the cancer returned even after prior treatments. New CAR T cell therapy treatments and new ways to use currently approved treatments are being studied in clinical trials.

Important Things to Know About Side Effects:

The CAR T infusion can cause side effects. Some patients experience severe side effects, while others experience mild or no side effects. Patients who start CAR T cell therapy will be told about all the possible side effects they might have. It is very important that patients tell their doctors about any side effects they experience. Most side effects can be managed if they are treated early.

These are the current CAR T cell therapies approved for treatment as of June 2024.

Search by Drug Name

Important Things to Know - All Drugs:

Cytokine Release Syndrome (CRS) may occur. This condition can cause flu-like symptoms, like fever and chills. Other conditions like neurotoxicity, tumor lysis syndrome, cytopenia, and B cell aplasia also may occur. These conditions can cause side effects, and some may be severe. Your healthcare team should discuss all potential side effects with you and your caregiver.

Learn about CAR T therapy and its side effects

Treatment Type

CAR T Cell Therapy

Drug Name
Kymriah® (tisagenlecleucel)
Who Can Use It?
Children and young adults up to 25 years of age

Approved to treat acute lymphoblastic leukemia (ALL) where:

  • The cancer didn’t respond to previous treatments
  • The cancer has returned for at least a second time
Adults

Approved to treat large B cell lymphomas where:

  • The cancer didn’t respond to previous treatments
  • The cancer returned despite 2 or more unsuccessful treatments
Drug Name
Yescarta® (axicabtagene ciloleucel)
Who Can Use It
Adults Approved to treat large B cell lymphoma where:
  • The cancer returned despite 1 or more unsuccessful treatments
Approved to treat follicular lymphoma where:
  • The cancer didn’t respond to previous treatments
  • The cancer returned despite 2 or more unsuccessful treatments
Drug Name
Tecartus™ (brexucabtagene autoleucel)
Who Can Use It
Adults Approved to treat mantle cell lymphoma (MCL) where:
  • The cancer returned despite 2 or more unsuccessful treatments
  • The cancer didn’t respond to previous treatments
Approved to treat B-cell precursor acute lymphoblastic leukemia (ALL) where:
  • The cancer returned despite 2 or more unsuccessful treatments
  • The cancer didn’t respond to previous treatments
Drug Name
Breyanzi™ (lisocabtagene maraleucel)
Who Can Use It
Adults

Approved to treat large B cell lymphoma where:

  • The cancer didn’t respond to previous treatments
  • The cancer returned despite 2 or more unsuccessful treatments

Approved to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when:

  • 2 or more kinds of treatment have not worked or stopped working
Drug Name
Abecma® (idecabtagene vicleucel)
Who Can Use It
Adults Approved to treat multiple myeloma where:
  • The cancer didn’t respond to previous treatments
  • The cancer returned despite 4 or more unsuccessful treatments
Drug Name
Carvykti® (ciltacabtagene autoleucel)
Important Things to Know

 

Adults

Approved to treat relapsed or refractory multiple myeloma where:  

  • The patient has had four or more prior lines of therapy 
  • The cancer returned following previous therapies